Aroa Biosurgery with Proactive at ASX Small and Mid Cap Conference

Aroa Biosurgery Ltd (ASX:ARX) CFO James Agnew sits down with Proactive's Tylah Tully live from the ASX Small and Mid Cap Conference in September 2024. Aroa describes itself as a soft-tissue regeneration company that develops, manufactures and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. The company, which was formerly called Mesynthes, initially contracted scientists from Industrial Research Ltd to get started and then rapidly transitioned to its own internal development team to accelerate commercialisation. Early in 2014, Aroa Biosurgery relocated and expanded into a new purpose-built facility in Auckland, New Zealand. Nowadays, Agnew says Aroa is committed to ‘unlocking regenerative healing for everybody’ and that more than 6.5 million AROA products have been used globally in a range of procedures to date. #ProactiveInvestors #AroaBiosurgery #ASX #SoftTissueRegeneration #RegenerativeHealing #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews